文献速递妇科

美国食品药品监督管理局关于子宫平滑肌瘤治疗中使用旋切器的安全通讯后反应的种族差异

Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
PubMed 文献 · J Minim Invasive Gynecol · 2019-03-30

本研究利用美国外科医师学会国家手术质量改进数据,回顾性队列分析18至55岁接受腹腔镜或开腹子宫肌瘤剔除术的患者,比较FDA安全通讯前后开腹手术相对腹腔镜手术的比值比在不同种族间的变化。调整混杂因素后,FDA通讯前后开腹子宫肌瘤剔除术的比值比为1.30(95%CI 1.20-1.41;p<.001);非洲裔人群较白人人群的比值比变化显著更大(1.22;95%CI 1.02-1.47;p=.03),其他种族无显著变化(0.83;95%CI 0.64-1.08;p=.17)。结论认为FDA通讯后非洲裔人群开腹子宫肌瘤剔除术的比值比不成比例地增加。

要点

  • FDA通讯前后开腹子宫肌瘤剔除术的比值比为1.30(95%CI 1.20-1.41;p<.001)。
  • 非洲裔人群较白人人群开腹手术比值比变化显著更大(1.22;95%CI 1.02-1.47;p=.03)。
  • 其他种族开腹手术比值比变化无显著差异(0.83;95%CI 0.64-1.08;p=.17)。

核心结论

  • FDA通讯后,非洲裔人群开腹子宫肌瘤剔除术的比值比不成比例地增加。

研究设计与样本

  • 回顾性队列研究,使用美国外科医师学会国家手术质量改进数据,纳入18至55岁接受腹腔镜或开腹子宫肌瘤剔除术的患者,排除恶性肿瘤、急诊手术、非妇科专科医师手术及剖宫产同时行子宫肌瘤剔除术的病例。

主要发现

  • 调整可能混杂因素后,全部种族中FDA通讯前后开腹子宫肌瘤剔除术的比值比为1.30(95%CI 1.20-1.41;p<.001)。
  • 以FDA通讯暴露与种族的乘积项作为可能效应修饰因子的逻辑回归分析中,非洲裔人群较白人人群开腹子宫肌瘤剔除术比值比变化显著更大(1.22;95%CI 1.02-1.47;p=.03)。
  • 其他种族开腹子宫肌瘤剔除术比值比变化无显著差异(0.83;95%CI 0.64-1.08;p=.17)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To investigate whether the rate of increase in the performance of abdominal myomectomy over a laparoscopic approach after the US Food and Drug Administration (FDA) safety communication regarding morcellator use for myomectomy differs among races. DESIGN: Retrospective cohort study. SETTING: The American College of Surgeons National Surgical Quality Improvement data. PATIENTS: Patients aged 18 to 55 years who underwent either laparoscopic or abdominal myomectomy, excluding malignant cases, emergency cases, operations performed by nongynecologic specialists, and cases in which myomectomy was performed during cesarean section. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The odds ratios of abdominal myomectomy over laparoscopic myomectomy before and after the release of the FDA communication were calculated in 3 race categories: white, African American, and other races. In a logistic regression analysis adjusted for possible confounders, including all races, the odds ratio of abdominal myomectomy before and after the FDA communication was 1.30 (95% confidence interval [CI], 1.20-1.41; p <.001). In a logistic regression analysis with a product term of FDA communication exposure and race as a possible effect modifier, the African American population showed a significantly greater change in the odds of abdominal myomectomy over laparoscopic myomectomy in comparison with the white population (1.22; 95% CI, 1.02-1.47; p = .03). In contrast, other races showed no significant change (.83; 95% CI, .64-1.08; p = .17). CONCLUSION: After the FDA communication, the odds ratio of abdominal myomectomy was disproportionately increased in the African American population.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Matsushita T, Sekizawa A, Jacobs LK, et al. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma. J Minim Invasive Gynecol. 2019. PMID: 30936031. doi:10.1016/j.jmig.2019.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。